Table 2.

Adjusted HRs for cardiovascular mortality and noncardiovascular mortality subsequent to an eGFR slope during a 3-year antecedent period for the other (general/high risk) cohorts (among 14 cohorts with available data)

OutcomeSlope Change in eGFR (ml/min per 1.73 m2 per yr) during the 3-yr Antecedent Period
−9−6−3Stable369
CV mortality
 Other cohorts1.33 (1.17 to 1.52)1.10 (0.98 to 1.22)1.08 (0.97 to 1.21)Reference1.12 (1.02 to 1.22)1.27 (1.10 to 1.46)1.46 (1.16 to 1.84)
Non-CV mortality
 Other cohorts1.29 (1.17 to 1.43)1.09 (1.03 to 1.15)1.03 (0.95 to 1.13)Reference1.02 (0.95 to 1.09)1.08 (0.95 to 1.23)1.31 (1.00 to 1.73)
  • Data are presented as adjusted HR (95% CI). CV, cardiovascular. The HR for eGFR slope was adjusted for age, sex, race (black versus nonblack), systolic BP, total cholesterol, diabetes, history of CVD, and current (last) eGFR.